Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received a notice from the State Drug Administration to approve the addition of a fifth indication to the Class 1 innovative drug emaxitinib sulfate tablets (SHR0302 tablets) independently developed by the company. Approved indications: This product is intended for adult patients with active radiologic negative axial spondyloarthritis who respond poorly or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs) and have objective signs of inflammation (expressed as elevated C-reactive protein [CRP] and/or abnormal magnetic resonance imaging (MRI)).

Zhitongcaijing · 1d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received a notice from the State Drug Administration to approve the addition of a fifth indication to the Class 1 innovative drug emaxitinib sulfate tablets (SHR0302 tablets) independently developed by the company. Approved indications: This product is intended for adult patients with active radiologic negative axial spondyloarthritis who respond poorly or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs) and have objective signs of inflammation (expressed as elevated C-reactive protein [CRP] and/or abnormal magnetic resonance imaging (MRI)).